Pii is Offering a $100,000 Grant for First-in-Human Program
The COVID-19 pandemic has changed our lives in unexpected ways. We shop differently, eat at restaurants less, and have limited our travel. Businesses has been impacted significantly with leadership learning how to effectively manage a distributed workforce. Business leaders are also re-thinking their strategies and adjusting their plans and expectations.
The pharmaceutical industry appears to be experiencing a shift in resources to more urgent, immediate needs related to the pandemic, leaving emerging biotech companies short on resources to even get through the remainder of the year. As much as 90% of you are scaling back your plans and reducing your evaluations.
At Pii we know that your scaled back projects are more than projects. They are promising therapies and somewhere a patient has planned for your success. That is the reason for this grant!
Over the next six weeks (this timeline may need adjusted based on Kurt’s feedback to Paul) Pii will review grant applications, seeking a promising early-stage therapy that best aligns with our capabilities to rapidly advance it to Phase I and on to a group of patients.
Our capabilities can support:
- Biologics and Vaccine fill-finish for Clinical Trial Manufacturing (CTM), as well as, formulation & process development.
- Projects for COVID-19 treatments and vaccines in clinical development.
- New Chemical Entities (NCE) and New Biological Entities (NBE) requiring formulation and process development, as well as, CTM.
- Clinical Trial Supplies for small molecules, biologics and vaccines.
Eligibility is contingent on the receipt form below.
If you believe you have a viable therapeutic candidate, complete the application below in detail. Applicants will be considered on project needs. The submission deadline is 5:00 PM EST August 15, 2020. Pii will award the recipient of the grant on Monday, August 31st, 2020.